CLU and breast cancer: reported that clusterin promotes the growth of BC and metformin targets clusterin to inactivate SREBP‐1c and its downstream target, FASN, resulting in the inhibition of de novo fatty acid synthesis, consequently inhibiting tumor growth in BC.